Point-of-Care Diagnostics Market 2018-2024

  • Report Id : AMP497543
  • Published On: Dec, 2019
  • Category : Diagnostics
  • Pages : 111
  • Ample Market Research

    Global Point-of-Care Diagnostics Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

    Overview: Point-of-care diagnostic test, also referred to as bedside testing or near-patient testing, is a medical diagnostic test conducted outside the laboratory at or near the place where the patient is receiving care. These tests are usually performed by non-laboratory personnel and test results are used for clinical decision making. The complexity and procedures for POC diagnostics may vary from manual methodologies to automated analyzers. These tests are comparatively more expensive than typical laboratory tests but are convenient and cost effective in some clinical settings since these are performed in close proximity to the patient. The best part is that these tests give immediate decisions for clinical management. According to a report released by the Centers for Disease Control and Prevention (CDC), in US alone currently more than 100 million adults are living with diabetes or prediabetes. Cardiovascular diseases (CVD) account for approximately 800,000 deaths in the US. On average, one person dies from CVD every 40 seconds in the US. CVD also causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. There is an increase in life style diseases and developing countries are also suffering from such ailments. It is primarily because of the increasing adoption of Western lifestyle which is expected to fuel the growth of point-of-care diagnostics market in near future.

    The point-of-care diagnostics market is booming due to several factors such as the growing patient base for lifestyle diseases globally, growing elderly population, increasing prevalence of infectious disease, technological innovations and increasing adoption of point-of-care diagnostics. Stringent approval processes, unfavorable reimbursement scenarios and product recalls are some of the factors hampering the market growth. The market in emerging countries is expected to grow at a rapid pace during the forecast period because of increasing healthcare awareness towards point-of-care diagnostics, increasing healthcare spending and growing patient pool.

    Market Analysis: The “Global Point-of-Care Diagnostics Market” is estimated to witness a CAGR of 7.7% during the forecast period 2018–2024. The market is analyzed based on four segments –products, prescription mode, end-users and regions.

    Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is set to be the leading region for the Point-of-Care Diagnostics market growth followed by Europe, Asia Pacific and the rest of the world.

    Product Analysis: The global Point-of-Care Diagnostics market by product is segmented into glucose monitoring kits, infectious diseases testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, coagulation monitoring kits, tumor/cancer markers, cholesterol test strips, drugs-of-abuse testing kits, and others. Glucose monitoring kits occupied the largest share in 2017 due to factors such as an increase in the prevalence of diabetes, change in lifestyle, growing elderly population and increasing demand for disease management.

    Prescription Mode Analysis: The global point-of-care diagnostics market by prescription mode is segmented into Prescription-based POC diagnostics and OTC-based POC diagnostics. The latter has occupied a major market share since 2017 and is expected to retain its position during the forecasted period with the introduction of hand-held and portable devices and increased awareness of POC diagnostics.

    End-Users Analysis: The global point-of-care diagnostics market by end-users is segmented into hospitals, clinics, home-care and others. Hospitals occupied the maximum market share in 2017 and is expected to be same for the next few years.

    Key Players: Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Siemens AG, Danaher Corporation, Qiagen N.V., BioMerieux S.A., Nova Biomedical, Beckton Dickinson and Company, Trinity Biotech plc and other niche players.

    Competitive Analysis: Currently, the glucose monitoring kits dominate the global point-of-care diagnostics market. A lot of new players are concentrating on this market to deliver advanced and innovative products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. For instance, in October 2017, Abbott completed the acquisition of Alere for about $5.3 billion. In January 2017, Werfen acquired Accriva Diagnostics, a global leader in in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC). The acquisition included Accriva’s flagship product portfolio spanning coagulation, platelet aggregation, CO-Oximetry and incision devices. Not only this but key players are also launching new products to have an edge in the market. For instance, in January 2018, Abbott Laboratories announced the launch of CE marked Alinity h-series integrated system for hematology testing.

    Benefits: The report provides complete details about the usage and adoption rate of point-of-care diagnostics products in various regions. With the help of this report, key stakeholders will find extensive details about the major trends, drivers, investments and vertical players’ initiatives. It will also shed light on government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on the market growth. Additionally, the report gives in-depth information about the key business opportunities to key stakeholders so that they can expand their businesses and forecast the revenue in specific verticals before investing or expanding their businesses in this market.

    Key Stakeholders:

     

  • Table of Contents

    1 INDUSTRY OUTLOOK 9

    1.1 Industry overview 10

    1.2 Total addressable market 10

    1.3 Industry Trends 11

    2 Report Outline 11

    2.1 Report Scope 11

    2.2 Report Summary 12

    2.3 Research Methodology 12

    2.4 Report Assumptions 13

    3 Market Snapshot 14

    3.1 Market Definition – Infoholic Research 14

    3.2 Advantages of Point-of-care testing 14

    3.3 Disadvantages of Point-of-care testing 14

    3.4 Segmented Addressable Market (SAM) 14

    3.5 Trends of the point-of-Care diagnostics market 15

    3.6 Related Markets 16

    3.6.1 Molecular diagnostics 16

    3.6.2 Infectious disease diagnostics 16

    4 Market Outlook 16

    4.1 Overview 16

    4.2 Funding scenario 17

    4.3 Market segmentation 19

    4.4 PEST Analysis 19

    4.5 Porter 5(Five) Forces 21

    5 Market Characteristics 22

    5.1 DRO – Global Point-of-care Diagnostics Market Dynamics 22

    5.1.1 Drivers 22

    5.1.1.1 Increasing prevalence of infectious disease 22

    5.1.1.2 Growing incidence of life-style disease 23

    5.1.1.3 Technological innovations 23

    5.1.1.4 Increasing adoption of point-of-care diagnostics 24

    5.1.2 Opportunities 24

    5.1.2.1 Growth opportunities in emerging markets 24

    5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries 25

    5.1.3 Restraints 25

    5.1.3.1 Stringent approval process 25

    5.1.3.2 Product recalls 26

    5.1.3.3 Unfavorable reimbursement scenario 26

    6 Product: Market Size and Analysis 29

    6.1 Overview 29

    6.2 Glucose monitoring kits 31

    6.3 Infectious disease testing kits 32

    6.4 Pregnancy and fertility testing kits 33

    6.5 Hematology testing kits 35

    6.6 Cardiometabolic monitoring kits 35

    6.7 Urinalysis testing kits 37

    6.8 Coagulation monitoring kits 38

    6.9 Tumour or cancer marker testing kits 39

    6.10 Cholesterol testing kits 40

    6.11 Drugs of abuse testing kits 40

    6.12 Others 41

    7 Prescription mode: Market Size and Analysis 42

    7.1 Overview 42

    7.2 Prescription-based point-of-care diagnostics 44

    7.3 Over the counter-based point-of-care diagnostics 45

    8 End Users: Market Size and Analysis 46

    8.1 Overview 46

    8.2 Hospitals 47

    8.3 Clinics 47

    8.4 Home-care 48

    8.5 Others 48

    9 Regions: Market Size and Analysis 49

    9.1 Overview 49

    9.2 North America 50

    9.2.1 Overview 50

    9.2.2 US 51

    9.2.3 Canada 52

    9.3 Europe 52

    9.3.1 Overview 52

    9.3.2 UK 53

    9.3.3 Germany 53

    9.3.4 France 54

    9.3.5 Spain 54

    9.4 APAC 54

    9.4.1 Overview 54

    9.4.2 India 55

    9.4.3 China 56

    9.5 Rest of the World 56

    10 Competitive Landscape 57

    10.1 Overview 57

    11 Vendor Profiles 61

    11.1 Abbott Laboratories 61

    11.1.1 Overview 61

    11.1.2 Business Unit 64

    11.1.3 Geographic Presence 65

    11.1.4 Business Focus 66

    11.1.5 SWOT Analysis 67

    11.1.6 Business Strategy 67

    11.2 F.Hoffmann-La Roche Ltd 68

    11.2.1 Overview 68

    11.2.2 Business Unit 71

    11.2.3 Geographic Presence 72

    11.2.4 Business Focus 73

    11.2.5 SWOT Analysis 73

    11.2.6 Business Strategy 74

    11.3 Johnson & Johnson 75

    11.3.1 Overview 75

    11.3.2 Business Units 78

    11.3.3 Geographic Revenue 79

    11.3.4 Business Focus 80

    11.3.5 SWOT Analysis 81

    11.3.6 Business Strategies 81

    11.4 Danaher Corporation 82

    11.4.1 Overview 82

    11.4.2 Business Unit 86

    11.4.3 Geographic Presence 86

    11.4.4 Business Focus 87

    11.4.5 SWOT Analysis 88

    11.4.6 Business Strategy 88

    11.5 Siemens Healthineers Inc. (Siemens AG) 89

    11.5.1 Overview 89

    11.5.2 Business Units 92

    11.5.3 Geographic Presence 94

    11.5.4 Business Focus 94

    11.5.5 SWOT Analysis 95

    11.5.6 Business Strategy 95

    12 Companies to Watch For 96

    12.1 Trinity Biotech plc 96

    12.1.1 Overview 96

    12.1.2 Trinity Biotech plc: Recent Developments 97

    12.2 Qiagen N.V. 97

    12.2.1 Overview 97

    12.2.2 Qiagen N.V.: Recent Developments 97

    12.3 BioMerieux S.A. 101

    12.3.1 Overview 101

    12.3.2 BioMerieux S.A.: Recent Developments 102

    12.4 OraSure Technologies, Inc. 103

    12.4.1 Overview 103

    12.4.2 OraSure Technologies, Inc.: Recent Developments 104

    12.5 Instrumentation Laboratory (a Werfen company) 104

    12.5.1 Overview 104

    12.5.2 Instrumentation Laboratory: Recent Developments 105

    12.6 Becton Dickinson and Company 106

    12.6.1 Overview 106

    12.6.2 Becton dickenson and company: Recent Developments 107

    12.7 Nova Biomedical 107

    12.7.1 Overview 107

    12.7.2 Nova Biomedical: Recent Developments 108

    13 Annexure 110

    13.1 Abbreviations 110

     

25% Off

This is a single user license, allowing one specific user access to the product.

This is a site license, allowing all users within a given geographical location of your organisation access to the product.

This is an enterprise license, allowing all employees within your organisation access to the product.

Need Assistance ?

Our Clients